Umecrine Cognition AB
Umecrine Cognition AB
04/30/2026 | Press release | Archived content
Notice to attend the Annual Shareholders’ Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)
Notice to attend the Annual Shareholders' Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)
April 30, 2026
The shareholders in Umecrine Cognition AB, reg. no. 556698- 3655, are hereby given notice to attend the annual general shareholders' meeting at 8:30 a.m. on Thursday 26 May 2026 at the company's offices at Nanna Svartz väg 2 in Solna, Sweden. Registration for the meeting commences at 08:10 (CEST). The complete notice can be found on the company's website (https://www.umecrinecognition.com/en/annual-general-meeting-2026/ ), including additional information concerning power of attorney forms and voting instructions, in Swedish and in English.
About Umecrine Cognition
Umecrine Cognition AB is developing a completely new class of drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation - a devastating brain distortion that can lead to severely impaired cognition and fatigue. Chronic neuroinflammation can occur as a result of a number of underlying conditions, including a range of liver diseases as well as neurodegenerative diseases, such as Parkinson's disease. Results from an internationally acclaimed Phase 2 clinical study indicate that the company's most advanced drug candidate, the GABAA receptor-modulating steroid antagonist golexanolone, normalizes brain signaling and improves cognition and alertness in patients with hepatic encephalopathy. A Phase 2 study is currently ongoing in patients with primary biliary cholangitis. Further, based on intriguing preclinical data, the company is considering pursuing the development of golexanolone in patients with Parkinson's disease. For more information, visit www.umecrinecognition.com.
For further information, please contact:
Viktor Drvota, CEO, Umecrine Cognition AB
Phone: +46 73 982 52 02, e-mail: [email protected]
Documents
IR contact
Subscribe
Umecrine Cognition AB published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 30, 2026 at 21:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]